CytoSorb has a safety track record. It has been used in more than 650 human treatments without serious device-related adverse events. (number from mid-2012).
In addition, I recently asked Dr Chan about cytokine removal (from their product brochure), that is probably close to answering your concern, here is his comment: "In terms of the cytokine data, the data on near complete removal is in horse serum. This is a different environment from whole blood which is significantly harder to remove cytokines from. The horse serum experiments indicate that the pores are ideally configured to remove a broad range of cytokines. But in whole blood, it is a much more complex milieu in which cytokines are often bound in equilibrium to cells and other whole blood components. As you lower plasma levels of cytokines, it shifts the equilibrium and more dissociates from the cellular reservoir and so on. In the influenza case report that is now in our investor presentation, you will note that cytokine extraction is very aggressive up front. This is based on concentration gradient and "driving force". As cytokine levels approach more reasonable levels in days 5-7 (still elevated but not toxic) the extraction efficiency drops off significantly. This is, in fact, important to the safety of our technology. We call it "self titration". Or in other words, the device "turns itself off" so to speak and it becomes much harder to over treat. Complete elimination of cytokines increases mortality in animal models of sepsis, probably because the immune system is then compromised. Our technology is more of an immunomodulation strategy that reduces cytokines to non-toxic levels to "reset" the immune response without ablating it."
